Development

pharma& is focused on the development of its own pipeline assets. We continue to develop our hematologic franchise, focusing on interferon and satraplatin.

In 2025, we initiated the protocol, setup, and drug supply for SAMOA, a phase 1/2 clinical trial of satraplatin in patients with relapsed or refractory primary central nervous system lymphoma (PCNSL), an ultra-rare hematological disease. Satraplatin has the potential to be the world’s first approved orally administered precision platinum therapy.